Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Copart
CPRT
$27.2B
| $22.7M | 0.02% |
+1,089,200
| New | +$21.9M |
|
|
STMP
752
DELISTED
Stamps.com, Inc.
STMP
| $22.6M | 0.02% |
123,200
+119,500
| +3,230% | +$20.4M |
|
753
TG Therapeutics
TGTX
$7.34B
| $22.5M | 0.02% |
1,155,400
+643,600
| +126% | +$10.4M |
|
|
MXIM
754
DELISTED
Maxim Integrated Products
MXIM
| $22.5M | 0.02% |
+371,200
| New | +$20.7M |
|
755
Ituran Location and Control
ITRN
$1.06B
| $22.4M | 0.02% |
1,396,000
+9,537
| +0.7% | +$157K |
|
756
Sony
SONY
$138B
| $22.2M | 0.02% |
1,606,500
-643,000
| -29% | -$8.36M |
|
757
Tractor Supply
TSCO
$18.8B
| $22.2M | 0.02% |
841,010
+653,040
| +347% | +$14.3M |
|
|
QTS
758
DELISTED
QTS REALTY TRUST, INC.
QTS
| $22.1M | 0.02% |
345,547
-37,953
| -10% | -$2.39M |
|
759
Ross Stores
ROST
$78.6B
| $22M | 0.02% |
258,428
-39,371
| -13% | -$3.57M |
|
760
EOG Resources
EOG
$74.2B
| $22M | 0.02% |
433,991
+66,291
| +18% | +$3.21M |
|
761
Methanex
MEOH
$4.19B
| $22M | 0.02% |
1,215,748
-164,300
| -12% | -$2.73M |
|
762
Rush Enterprises Class A
RUSHA
$9.62B
| $21.9M | 0.02% |
1,190,090
+168,300
| +16% | +$2.8M |
|
763
US Physical Therapy
USPH
$1.24B
| $21.9M | 0.02% |
269,723
+57,210
| +27% | +$4.17M |
|
|
DRD
764
DRDGold
DRD
$2.06B
| $21.8M | 0.02% |
1,382,613
+188,200
| +16% | +$1.86M |
|
765
SolarEdge
SEDG
$1.98B
| $21.8M | 0.02% |
157,300
-44,800
| -22% | -$5.48M |
|
766
Domo
DOMO
$187M
| $21.8M | 0.02% |
+676,400
| New | +$15.1M |
|
767
Tootsie Roll Industries
TR
$3.02B
| $21.8M | 0.02% |
757,815
+351,724
| +87% | +$10.4M |
|
768
Vishay Precision Group
VPG
$908M
| $21.7M | 0.02% |
883,874
+34,500
| +4% | +$776K |
|
769
Carlisle Companies
CSL
$14.9B
| $21.7M | 0.02% |
181,500
+116,500
| +179% | +$14M |
|
770
Brown & Brown
BRO
$24B
| $21.7M | 0.02% |
532,600
-1,005,857
| -65% | -$38.8M |
|
|
BMTC
771
DELISTED
Bryn Mawr Bank Corp
BMTC
| $21.7M | 0.02% |
784,120
-7,038
| -0.9% | -$191K |
|
|
BMY.RT
772
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $21.7M | 0.02% |
6,054,060
-3,372,100
| -36% | -$12.2M |
|
773
Weis Markets
WMK
$1.77B
| $21.7M | 0.02% |
432,411
+240,064
| +125% | +$12M |
|
|
VNET
774
VNET Group
VNET
$2.12B
| $21.6M | 0.02% |
907,100
-146,900
| -14% | -$2.37M |
|
775
Emcor
EME
$36.7B
| $21.6M | 0.02% |
327,000
+151,700
| +87% | +$9.5M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.